Cargando…
Molecular targeted therapy for advanced or metastatic soft tissue sarcoma
Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarco...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727831/ https://www.ncbi.nlm.nih.gov/pubmed/34844463 http://dx.doi.org/10.1177/10732748211038424 |
_version_ | 1784626599121911808 |
---|---|
author | Yuan, Jin Li, Xiaoyang Yu, Shengji |
author_facet | Yuan, Jin Li, Xiaoyang Yu, Shengji |
author_sort | Yuan, Jin |
collection | PubMed |
description | Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarcomas, and chemotherapy is the additional option for those with high-risk. However, not all patients with advanced or metastatic soft tissue sarcomas benefit from conventional chemotherapy, targeted therapy takes the most relevant role in the management of those resistant to or failed to conventional chemotherapy. Heterogeneous soft tissue sarcomas vary from biological behavior, genetic mutations, and clinical presentation with a low incidence, indicating the future direction of histotype-based even molecule-based personalized therapy. Furthermore, increasing preclinical studies were carried out to investigate the pathogenesis and potential therapeutic targets of soft tissue sarcomas and increasing new drugs have been developed in recent years, which had started opening new doors for clinical treatment for patients with advanced/metastatic soft tissue sarcomas. Here we sought to summarize the concise characteristics and advance in the targeted therapy for the most common subtypes of soft tissue sarcomas. |
format | Online Article Text |
id | pubmed-8727831 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-87278312022-01-06 Molecular targeted therapy for advanced or metastatic soft tissue sarcoma Yuan, Jin Li, Xiaoyang Yu, Shengji Cancer Control Review Soft tissue sarcomas are a form of rare and heterogeneous neoplasms with high recurrence rate and mortality. Over the past decades, less progress has been achieved. Surgical management with or without adjuvant/neoadjuvant radiotherapy is still the first-line treatment for localized soft tissue sarcomas, and chemotherapy is the additional option for those with high-risk. However, not all patients with advanced or metastatic soft tissue sarcomas benefit from conventional chemotherapy, targeted therapy takes the most relevant role in the management of those resistant to or failed to conventional chemotherapy. Heterogeneous soft tissue sarcomas vary from biological behavior, genetic mutations, and clinical presentation with a low incidence, indicating the future direction of histotype-based even molecule-based personalized therapy. Furthermore, increasing preclinical studies were carried out to investigate the pathogenesis and potential therapeutic targets of soft tissue sarcomas and increasing new drugs have been developed in recent years, which had started opening new doors for clinical treatment for patients with advanced/metastatic soft tissue sarcomas. Here we sought to summarize the concise characteristics and advance in the targeted therapy for the most common subtypes of soft tissue sarcomas. SAGE Publications 2021-11-29 /pmc/articles/PMC8727831/ /pubmed/34844463 http://dx.doi.org/10.1177/10732748211038424 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Yuan, Jin Li, Xiaoyang Yu, Shengji Molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
title | Molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
title_full | Molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
title_fullStr | Molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
title_full_unstemmed | Molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
title_short | Molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
title_sort | molecular targeted therapy for advanced or metastatic soft tissue sarcoma |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8727831/ https://www.ncbi.nlm.nih.gov/pubmed/34844463 http://dx.doi.org/10.1177/10732748211038424 |
work_keys_str_mv | AT yuanjin moleculartargetedtherapyforadvancedormetastaticsofttissuesarcoma AT lixiaoyang moleculartargetedtherapyforadvancedormetastaticsofttissuesarcoma AT yushengji moleculartargetedtherapyforadvancedormetastaticsofttissuesarcoma |